Wave Life Sciences Ltd. (WVE) Stock Score, Valuation & Financial Research
Wave Life Sciences Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 37/100.
Quick answer for WVE
Wave Life Sciences Ltd. currently has a Wall Street Score of 37/100. The stored market price is $4.46. Its financial score is 50/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Wave Life Sciences Ltd. does
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington
WVE financial snapshot
- Wall Street Score:
- 37/100
- Current price:
- $4.46
- Market capitalization:
- $878.8M
- Revenue:
- $71.8M
- Net income:
- $-183.6M
- Free cash flow:
- $-188.2M
- Cash:
- $544.6M
- Total debt:
- $15.7M
- EPS:
- -1.21
- Financial score:
- 50/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is +0.7%.
- Free cash flow is $-188.2M, showing cash burn in the current stored period.
- The balance sheet shows $544.6M of cash versus $15.7M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research WVE
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.